Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

Podrobná bibliografie
Hlavní autoři:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
Médium:	Journal article
Jazyk:	English
Vydáno:	MDPI 2020

Podobné jednotky

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
Autor: Laura C. Zanetti-Domingues, a další
Vydáno: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
Autor: Zanetti-Domingues, LC, a další
Vydáno: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
Autor: Laura C. Zanetti-Domingues, a další
Vydáno: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
Autor: Xu H, a další
Vydáno: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
Autor: M. Pérez-Capó, a další
Vydáno: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Autor: Lihua Huang, a další
Vydáno: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
Autor: Lu Yang, a další
Vydáno: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
Autor: Yao Li, a další
Vydáno: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
Autor: J.-H. Lee, a další
Vydáno: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
Autor: Cornelius Hempel, a další
Vydáno: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
Autor: Igor Makhlin, a další
Vydáno: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
Autor: Katri Vaparanta, a další
Vydáno: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
Autor: Tasia Amelia, a další
Vydáno: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
Autor: Barnabas Irmer, a další
Vydáno: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Autor: Aude I. Ségaliny, a další
Vydáno: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
Autor: Panupong Mahalapbutr, a další
Vydáno: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
Autor: Ramya Lakshmi Rajendran, a další
Vydáno: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Autor: Shannon S. Zhang, MD, a další
Vydáno: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
Autor: Kenichi Suda, a další
Vydáno: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
Autor: Xingyuan Li, a další
Vydáno: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
Autor: Zhenfang Du, a další
Vydáno: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
Autor: Kinlin L Chao, a další
Vydáno: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
Autor: Rocío Mato-Basalo, a další
Vydáno: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
Autor: Marcin Skrzypski, a další
Vydáno: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
Autor: Keigo Kobayashi
Vydáno: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Autor: Daniel B Costa, a další
Vydáno: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
Autor: Xuedi Zhang, a další
Vydáno: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
Autor: Zhe Zhang, a další
Vydáno: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
Autor: Tim Fischer, a další
Vydáno: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
Autor: K. K. Laktionov, a další
Vydáno: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
Autor: Tatsuki Shibuta, a další
Vydáno: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
Autor: Hao Huang
Vydáno: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
Autor: Sassan Hafizi
Vydáno: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
Autor: Kenji Hanamura, a další
Vydáno: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
Autor: Ichiro N. Maruyama
Vydáno: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
Autor: Jihene Elloumi-Mseddi, a další
Vydáno: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
Autor: Nathaniel J. Myall, MD, a další
Vydáno: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
Autor: D. D. SAKAEVA
Vydáno: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
Autor: Soomin Kim, a další
Vydáno: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
Autor: Wu Z, a další
Vydáno: (2019-10-01)